Utah Medical Products, Inc.
NASDAQ•UTMD
CEO: Mr. Kevin L. Cornwell
セクター: Healthcare
業種: Medical - Instruments & Supplies
上場日: 1999-03-08
Utah Medical Products, Inc. develops, manufactures, and distributes medical devices for the healthcare industry worldwide. It offers fetal monitoring accessories, vacuum-assisted delivery systems, and other labor and delivery tools; DISPOSA-HOOD infant respiratory hoods; and DELTRAN PLUS blood pressure monitoring systems. It also provides GESCO, an umbilical vessel catheters, including DIALY-NATE disposable peritoneal dialysis sets; PALA-NATE silicone oral protection devices; URI-CATH urinary drainage systems; NUTRI-CATH\NUTRI-LOK feeding device; PICC-NATE, a percutaneous intraepithelial central venous catheter; MYELO-NATE lumbar sampling kits; HEMO-NATE disposable filters; and catheterization procedure tray of instruments and supplies. In addition, the company offers LETZ system to excise cervical intraepithelial neoplasia and other lower genital tract lesions; loop, ball, and needle electrodes; FILTRESSE evacuators; other specialty electrodes and supplies, and gynecologic tools; Femcare trocars, cannulae, laparoscopic instruments, and accessories; and EPITOME and OptiMicro electrosurgical devices. Further, it provides Filshie Clip female surgical contraception devices; PATHFINDER PLUS, an endoscopic irrigation devices; suprapubic catheterization; LIBERTY, an urinary incontinence treatment and control systems; ENDOCURETTE, a curette for uterine endometrial tissue sampling; TVUS/HSG-Cath to assess abnormal or dysfunctional uterine bleeding and other abnormalities of uterus; and LUMIN, a tool to manipulate the uterus in laparoscopic procedures. Additionally, it offers DELTRAN, a disposable pressure transducer; high-pressure and piezo-resistive transducer assemblies; and pressure monitoring accessories, components, and other molded parts. It serves neonatal intensive care units, labor and delivery departments, women's health centers in hospitals, outpatient clinics, and physician's offices. The company was incorporated in 1978 and is headquartered in Midvale, Utah.
連絡先情報
時価総額
$205.36M
PER (TTM)
18.8
65.7
配当利回り
1.9%
52週高値
$65.00
52週安値
$51.26
52週レンジ
順位18Top 5.0%
6.3
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
強い • 6.3 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025
財務ダッシュボード
Q4 2025 データ
売上高
$9.04M-1.24%
直近4四半期の推移
EPS
$0.77-10.46%
直近4四半期の推移
フリーCF
$0.00+0.00%
直近4四半期の推移
2025 Q3 決算ハイライト
主なハイライト
Strong Cash Position Maintained Cash and investments total $84.3M as of September 30, 2025, showing slight period-over-period growth from year-end 2024.
EPS Supported by Buybacks Diluted EPS decreased 13.5% to $2.68 for 9M 2025, mitigated by share repurchases reducing the outstanding share count.
Balance Sheet Remains Solid Total assets slightly decreased to $122.0M; total liabilities dropped to $3.72M, maintaining a low total debt ratio of 3%.
Capital Return Activity Used $7.36M cash for share repurchases in 9M 2025, supporting stockholder value despite lower overall net income results.
リスク要因
OUS Distributor Order Loss Unexpected cancellation of OUS distributor orders resulted in $581K revenue loss during the third quarter period.
Gross Margin Compression 9M Gross Profit Margin fell to 56.8% from 59.3% due to lower sales absorption and increased manufacturing tariffs.
Bad Debt Provision Taken Recorded $395K bad debt expense in 3Q 2025 related to China distributor issues, significantly reducing operating income.
Operating Income Declines 3Q Operating Income fell 21.9% to $2.61M, driven by lower sales and higher operating expenses as a percentage of sales.
見通し
Revised Full Year Guidance Full year 2025 revenues now expected 6-7% lower than 2024 due to ongoing OUS distributor demand contraction.
Expected EPS Range Management projects full year 2025 EPS to fall within the narrow range of $3.40 to $3.50 per share.
Strategic Growth Focus Plan includes introducing high-pressure transducer configurations directly to biopharma manufacturers for future revenue growth.
Cash Allocation Strategy Utilize positive cash flow for dividends, opportunistic share repurchases when stock appears undervalued, and acquisitions.
同業比較
売上高 (TTM)
ATLN$445.38M
INFU$141.05M
STIM$129.87M
粗利益率 (最新四半期)
83.7%
74.3%
CHRS67.8%
主要指標
銘柄コード | 時価総額 | PER (TTM) | ROE (TTM) | 負債比率 |
|---|---|---|---|---|
| CATX | $349.39M | -3.3 | -39.1% | 1.1% |
| ACRS | $345.62M | -2.8 | -102.8% | 1.3% |
| PRE | $290.92M | -6.6 | -28.9% | 1.1% |
長期トレンド
直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
-2.3%
横ばい
4四半期純利益CAGR
-5.5%
収益性の低下
キャッシュフロー安定性
75%
キャッシュフローの変動が大きい
深度リサーチ
次回決算:2026年4月27日
EPS:-
|売上高:-
財務レポート
財務データ
全年度
Form 10-Q - Q3 2025
会計期末: 2025年9月30日|提出日: 2025年11月14日|売上高: $9.81M-1.9%|EPS: $0.79-22.5%不明Form 10-Q - Q2 2025
会計期末: 2025年6月30日|提出日: 2025年8月12日|売上高: $9.95M-4.3%|EPS: $0.92-3.2%不明Form 10-Q - Q1 2025
会計期末: 2025年3月31日|提出日: 2025年5月15日|売上高: $9.71M-14.4%|EPS: $0.92-15.6%不明Form 10-K - FY 2024
会計期末: 2024年12月31日|提出日: 2025年3月26日|売上高: $40.90M-18.6%|EPS: $3.96-13.3%不明Form 10-Q - Q3 2024
会計期末: 2024年9月30日|提出日: 2024年11月12日|売上高: $10.01M-20.0%|EPS: $1.02-5.6%予想を下回るForm 10-Q - Q2 2024
会計期末: 2024年6月30日|提出日: 2024年8月9日|売上高: $10.40M-19.2%|EPS: $0.95-18.1%予想を下回るForm 10-Q - Q1 2024
会計期末: 2024年3月31日|提出日: 2024年5月10日|売上高: $11.34M-9.4%|EPS: $1.09-6.0%予想を下回るForm 10-K - FY 2023
会計期末: 2023年12月31日|提出日: 2024年3月26日|売上高: $50.22M-3.9%|EPS: $4.57+0.9%予想を上回る